These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19118045)

  • 41. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
    Su Y; Ortiz J; Liu S; Bugge TH; Singh R; Leppla SH; Frankel AE
    Cancer Res; 2007 Apr; 67(7):3329-36. PubMed ID: 17409442
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling.
    Cohen R; Vugts DJ; Visser GW; Stigter-van Walsum M; Bolijn M; Spiga M; Lazzari P; Shankar S; Sani M; Zanda M; van Dongen GA
    Cancer Res; 2014 Oct; 74(20):5700-10. PubMed ID: 25145670
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
    Yu JM; Li YJ; Qiu LY; Jin Y
    J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
    Rice JR; Gerberich JL; Nowotnik DP; Howell SB
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
    Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP
    Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
    Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
    Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
    Hamblett KJ; Senter PD; Chace DF; Sun MM; Lenox J; Cerveny CG; Kissler KM; Bernhardt SX; Kopcha AK; Zabinski RF; Meyer DL; Francisco JA
    Clin Cancer Res; 2004 Oct; 10(20):7063-70. PubMed ID: 15501986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytotoxic evaluation of injectable cyclodextrin nanoparticles.
    Memisoglu-Bilensoy E; Doğan AL; Hincal AA
    J Pharm Pharmacol; 2006 May; 58(5):585-9. PubMed ID: 16640826
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Basic HGF-like peptides inhibit generation of liver metastases in murine and human tumor models.
    Fazekas K; Rásó E; Zarándi M; Dudás J; Tímár J
    Anticancer Res; 2002; 22(5):2575-9. PubMed ID: 12529966
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TTI-237: a novel microtubule-active compound with in vivo antitumor activity.
    Beyer CF; Zhang N; Hernandez R; Vitale D; Lucas J; Nguyen T; Discafani C; Ayral-Kaloustian S; Gibbons JJ
    Cancer Res; 2008 Apr; 68(7):2292-300. PubMed ID: 18381436
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
    Janssen S; Rosen DM; Ricklis RM; Dionne CA; Lilja H; Christensen SB; Isaacs JT; Denmeade SR
    Prostate; 2006 Mar; 66(4):358-68. PubMed ID: 16302271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models.
    Yu NY; Conway C; Pena RL; Chen JY
    Anticancer Res; 2007; 27(4B):2541-5. PubMed ID: 17695551
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anticancer efficacy of methioninase in vivo.
    Tan Y; Xu M; Guo H; Sun X; Kubota T; Hoffman RM
    Anticancer Res; 1996; 16(6C):3931-6. PubMed ID: 9042315
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel polymeric prodrug with multivalent components for cancer therapy.
    Khandare JJ; Chandna P; Wang Y; Pozharov VP; Minko T
    J Pharmacol Exp Ther; 2006 Jun; 317(3):929-37. PubMed ID: 16469865
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma.
    Budak-Alpdogan T; Chen B; Warrier A; Medina DJ; Moore D; Bertino JR
    Clin Cancer Res; 2009 Feb; 15(4):1232-40. PubMed ID: 19174488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies.
    Supino R; Petrangolini G; Pratesi G; Tortoreto M; Favini E; Bo LD; Casalini P; Radaelli E; Croce AC; Bottiroli G; Misiano P; Farina C; Zunino F
    J Pharmacol Exp Ther; 2008 Jan; 324(1):15-22. PubMed ID: 17909082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
    Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models.
    Tejeda M; Gaal D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri GY
    Anticancer Res; 2008; 28(5A):2769-74. PubMed ID: 19035308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.